Prof Clare Scott
Professor of Gynaecological Cancer
Department of Obstetrics, Gynaecology and Newborn Health
633 Scholarly works
5 Projects
HIGHLIGHTS
2024
Journal article
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance
DOI: 10.1186/s12943-024-02048-12022
Research Contracts
Salary Contribution Ci Clare Scott 22/23
2020
Research Grant
A Multiple Modality Approach for Targeting Chemotherapy-and Parpi-Resisatnt Ovarian Cancer
2018
Journal article
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
DOI: 10.1038/s41467-018-05564-z2017
Journal article
Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma
DOI: 10.1158/2159-8290.CD-17-04192017
Research Grant
Stics and Stones: A Randomised Phase Ii Double-Blind Placebo-Controlled Trial of Acetylsalicylic Acid (Asa) in Chemoprevention of Ovarian Cancer in Women With Brca1 and Brca2 Mutations
2016
Conference Proceedings
Secondary mutations in RAD51C and RAD51D are associated with acquired resistance to the PARP inhibitor rucaparib in patients with high-grade ovarian cancer
DOI: 10.1016/S0959-8049(16)32627-2
RECENT SCHOLARLY WORKS
2026
Journal article
High-throughput drug screening identifies EGFR/MAPK pathway targeting sensitivities in organoid models of ovarian carcinosarcoma
DOI: 10.1186/s13046-025-03629-82026
Journal article
Ovarian cancer
DOI: 10.1038/s41572-026-00686-x2026
Journal article
Epidemiology of sinonasal undifferentiated carcinoma in Queensland, Australia, 1982-2024: insights from a population-based cohort
DOI: 10.1016/j.esmorc.2026.1005392026
Journal article
PARP Inhibitors in the Management of Ovarian Cancer: ASCO Living Guideline, Version 2026.1.0.
DOI: 10.1200/JCO-26-024122026
Journal article
Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial
DOI: 10.1038/s41416-026-03535-62026
Journal article
PARAGON-II cohort C: a phase II basket study of letrozole plus ribociclib in hormone receptor-positive, platinum-resistant, high-grade epithelial ovarian cancer.
DOI: 10.1016/j.ijgc.2026.1056002026
Journal article
PARAGON-II COHORT C: A PHASE II BASKET STUDY OF LETROZOLE PLUS RIBOCICLIB IN HORMONE RECEPTOR POSITIVE PLATINUM-RESISTANT HIGH-GRADE EPITHELIAL OVARIAN CANCER
DOI: 10.1016/j.ijgc.2026.1051252026
Journal article
RAD54L coordinates the nucleolar DNA damage response to maintain rDNA stability
DOI: 10.1038/s44318-026-00864-3